INMD Inmode

inmodemd.com/about/

InMode Ltd. is a leading global provider of innovative and award winning medical technologies that focuses on well-being and life-changing results. InMode develops, manufacturers, and markets platforms that harness novel radio-frequency (RF) based technology that strives to enable new emerging minimally-invasive procedures and improve existing surgical procedures. InMode has leveraged its medically-accepted RF technologies to offer a comprehensive line of platforms that will enable us to capitalize on a multi-billion dollar market opportunity across several categories of surgical specialty such as plastic surgery, gynecology, dermatology, ENT’s and ophthalmologists.

www.marketscreener.com/INMODE-LTD-63383136/

www.fool.com/investing/2019/08/14/...de-is-soaring-today.aspx

seekingalpha.com/symbol/INMD?s=inmd

Q3 kommen am 5.11.19. IPO 2019

Q2 war stark. Erklärt auch den Anstieg.

www.marketscreener.com/INMODE-63383136/...illion-Re-29060235/

InMode Receives Health Canada Certification for Multiple New Products

seekingalpha.com/pr/...da-certification-multiple-new-products

tolle Aktie.

Die Aktie ist noch nicht besonders lang an der Börse. Deshalb wohl von  Ariva noch nicht unterstützt.  Heute gab es einen schönen Kursanstieg. Vielleicht wusste da schon jemand etwas zu den morgigen Zahlen. Ansonsten kann es morgen auch wieder Kursabschläge geben.  

ein Paar gekauft. Leider etwas zu früh;( Der Kurs ist schon wieder deutlich zurück gekommen. Schauen wir mal was die Zeit bringt.  

Das israelische Medizintechnik-Unternehmen InMode (37,460 $ 10,27 %) blickt auf ein erfolgreiches erstes Quartal an der Börse zurück und kann nun erneut mit den berichteten Zahlen überzeugen.

Analysten hatten im Durchschnitt einen Umsatz von 35,5 Mio. USD und EPS von 0,3 USD erwartet.

3. Quartal 2019:
Umsatz: 40 Mio. USD -> + 57%
Nettogewinn: 16,2 Mio. USD -> + 87%
EPS: 0,42 USD

Vorbörslich steht der Kurs aktuell bei rund 39 USD, welches einem Plus von rund 14% im Vergleich zum gestrigen Schlusskurs entspricht.

Hier noch einmal ausführlich:

www.marketscreener.com/...ts-Growth-of-57-Year-Over-29518290/

Die lassen sich die Sachen gut bezahlen:

www.inmodemd.co.uk/consumables

inmoderesources.com/wp-content/uploads/...rder-Form-011117.pdf

seekingalpha.com/article/...nings-call-transcript?part=single

research.investors.com/stock-lists/ibd-50/

denke bei einem starken Kurs Rückgang steige ich wieder ein! Die Aktie ist als Kurz- oder Mittelfristige Anlage gut geeignet, meiner Meinung nach

So schnell kann es gehen. Könnte schon soweit sein.  

www.nasdaq.com/articles/...ocks-to-buy-in-november-2019-11-21

1. A noninvasive surgical stock
A tiny Israeli company has a new, noninvasive way to perform plastic surgery using radio waves. So far, the market reception has been incredible. InMode IPO'd at $14 a share in August. Three months later, the stock is trading at $54 a share. Why is it running up?
The company reported Q3 earnings on Nov. 5 and its latest numbers are really nice. Revenue grew by 57% to $40 million. Profits grew by 62% to $0.42 a share. InMode has almost no debt ($922,000) and $166 million in cash. The company is still very small, with a market capitalization of $1.74 billion. Management is projecting $150 million in revenue for 2019, up from $100 million last year.

There are more than 8,000 plastic surgeons in the U.S. InMode has captured over 2,400 U.S. customers, so it's already made a sizable dent in its largest market. It is synonymous with using radio waves to avoid surgery or lasers. The Forma "noninvasive face-lift" is popular with many celebrities, including Kim Kardashian, Chrissy Teigen, and Emma Roberts.
The company does not give a total addressable market in its S-1, but cites the American Society for Aesthetic Plastic Surgery for the fact that U.S. consumers spent $8.5 billion on aesthetic procedures in 2017. The market for plastic surgery instruments is a niche market, estimated to be worth almost $1 billion in the U.S. The company is currently trading at 47 times trailing earnings, suggesting much of its future growth is already priced in.

www.investors.com/news/technology/...rc=A00220&yptr=yahoo

InMode (INMD) crushed 2020 guidance expectations Tuesday following a fourth-quarter beat — but INMD stock went from a massive gain to losses in early action.

For the fourth quarter ended Dec. 31, adjusted InMode earnings of 46 cents per share more than doubled year over year, rising 109%. On average, analysts polled by Zacks Investment Research expected InMode to earn 39 cents a share.

Sales rocketed 63% to $47 million. That topped estimates by $4 million.

In early trading on the stock market today, INMD stock initially popped as high as 10.6%, but shares lost 3.8% near 42.30, in more recent action. INMD stock is closing in on a buy point at 53.30 out of a cup-with-handle base.

www.marketscreener.com/...ar-2019-Financial-Results-30011974/

Fourth Quarter 2019 Highlights:

Record quarterly revenue of $47 million, an increase of 63% compared to the fourth quarter in 2018
GAAP net income attributable to InMode Ltd. of $19.0 million, compared to a $0.2 million loss attributable to InMode Ltd. in the fourth quarter in 2018; *non-GAAP net income attributable to InMode Ltd. of $19.3 million
GAAP and *non-GAAP fully diluted earnings per share of $0.46
Total cash position of $193.4 million as of December 31, 2019, including cash and cash equivalents, marketable securities and short-term bank deposits
Full Year 2019 Highlights:

Record full year revenue of $156.4 million, an increase of 56% as compared to 2018
GAAP net income attributable to InMode Ltd. of $61.1 million, a 173% increase year-over-year; *non-GAAP net income attributable to InMode Ltd. of $62.4 million, a 95% increase year-over-year
GAAP fully diluted earnings per share of $1.60, an increase of 158% as compared to 2018; *non-GAAP fully diluted earnings per share of $1.63, an increase of 81% year-over-year
68% increase in international (non-U.S.) revenue as compared to 2018

2020 Financial Outlook

Management provided an outlook for the full year of 2020, the period ending December 31, 2020. Based on current estimates, management expects:

$190 million to $198 million in revenue
85%-87% in Gross Margins
*Non-GAAP Income from Operations - $76 million to $80 million
*Non-GAAP Earnings per Diluted Share - $1.85 - $1.93
This outlook is not guarantee of future performance and stockholders should not place under reliance on such forward-looking statements. See "Forward-Looking Statements" for additional information.

Quartalszahlen abverkauft werden. Jetzt bin ich klein rein mit 25 Stück zu 41,65 US $. Mal sehen wo die Reise hin Geht

Moin Leude,

wie genau kann ich mir die Aktie kaufen. Auf Comdirect werden amerikanische Banken gelistet, jedoch ohne Preis. Es wird nur z.B. Goldman Sachs -- angegeben.

Merci im Vorraus

www.marketscreener.com/quote/stock/...ings-Snapshot-32406539/